Sofinnova Investments related stories
All articles and analysis
VC-backed Versartis raises $126 mln for IPOVersartis has launched its IPO after pricing its 6 million shares at $21 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "VSAR." Morgan Stanley and Citigroup are the lead underwriters. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency. Its backers include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.
- ZS Pharma racks up $55 mln in Series D funds
ZS Pharma has raised $55 million in Series D financing. Novo A/S led the round with participation from RA Capital, Adage Capital, Sofinnova Ventures, Alta Partners, Devon Park Bioventures, 3x5 Special Opportunity Fund, Salem Partners and RiverVest. Based in Coppell, Texas, ZS Pharma is a specialty pharmaceutical company focused on treating kidney, cardiovascular and liver disorders.
- Versartis rakes in $55 mln in Series E funds
Versartis has closed $55 million in Series E financing. The investors include return backers Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences. Based in Redwood City, Calif., Versartis is an endocrine-focused biopharmaceutical company focused on treating growth hormone deficiency.
- First Aid Shot Therapy completes Series B
Consumer healthcare company First Aid Shot Therapy has completed a Series B financing round. Sofinnova Ventures and Redmile Group co-led the round with additional support from investors including Sofinnova HealthQuest, Clearwell Group and Mark Rampolla, founder and former CEO of ZICO Beverages, maker of ZICO Pure Premium Coconut Water.
- Artiman Ventures appoints new MD
Artiman Ventures has appointed Brian Wilcove as a managing director. Wilcove will concentrate on identifying, investing and helping grow early stage enterprise technology companies with the potential to disrupt existing multibillion dollar markets or create entirely new ones.
- Versartis appoints Sofinnova's Shepard as executive chairman
Versartis said Wednesday that it has named Jay Shepard as executive chairman to its board of directors. Shepard is currently an executive partner at Sofinnova Ventures. Based in Redwood City, Calif., Versartis is a biotechnology company focused on developing treatments for patients with endocrine disorders.
- Vestagen Technical Textiles raises $7.3 mln funding round extension
Vestagen Technical Textiles, develops and markets advanced performance textile products, has raised an additional $7.3 million in an extension of its recent financing round. Existing investor Advent Life Sciences was joined in the extension by new investors Sofinnova HealthQuest Capital and the Clearwell Group. The extension brings the total raised by Vestagen in this financing round to $15.5 million. In connection with the funding extension, Randy Scott, partner at Sofinnova HealthQuest Capital, is joining the Vestagen board of directors.
Fund performance: UTIMCO’s mid-decade venture funds perform wellUnion Square, Spark and Foundry Group top the list of winners
Fund performance: San Francisco LP sees impressive start to recent venture fundsFunds from Polaris, Trinity and NEA are quick out of the blocks